Investors

Blade Therapeutics is backed by a premier investment syndicate, including MPM Capital, Deerfield Management, and Osage University Partners, as well as strategic and equity pharma investors Bristol-Myers Squibb, Novartis Institutes for Biomedical Research, and Pfizer Venture Investments.